---
schema_version: "secwatch.filing_event.v1"
accession: "0002007919-26-000010"
form_type: "8-K"
ticker: "INBX"
cik: "0002007919"
company_name: "Inhibrx Biosciences, Inc."
filed_at: "2026-04-21T23:59:59+00:00"
generated_at: "2026-05-15T05:11:02.221712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Inhibrx reports 20% ORR with ozekibart combo in late-line CRC; BLA submitted for chondrosarcoma

## Summary
- ORR of 20% in 45 evaluable patients vs historical 1-6% for standard of care; responses durable >6 months.
- Median PFS 5.5 months; 42% progression-free at 6 months; DCR 87%.
- Manageable safety, mostly Grade 1-2 diarrhea, fatigue, nausea; no significant liver toxicity despite 68% with liver metastases.
- Plans to meet FDA in H2 2026 for first-line registrational trial; accelerate pathways for 4th-line CRC and refractory Ewing sarcoma.
- BLA submitted to FDA for ozekibart in conventional chondrosarcoma in April 2026.

## SEC filing metadata
- accession: 0002007919-26-000010
- form_type: 8-K
- ticker: INBX
- cik: 0002007919
- company_name: Inhibrx Biosciences, Inc.
- filed_at: 2026-04-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/0002007919-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2007919/000200791926000010/inhibrx-20260421.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002007919-26-000010
- JSON: https://secwatch.observer/filing/0002007919-26-000010.json
- Plain text: https://secwatch.observer/filing/0002007919-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.